Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Diseases of Poverty Pay?

This article was originally published in Start Up

Executive Summary

Medicines to fight significant global health problems are scarce because the lack of commercial return trumps the fact that drug targets are well characterized and the required R&D investment is relatively inexpensive. The Gates Foundation hopes to create a more robust marketplace for global health medicines through non-dilutive funding. Gates money, plus Priority Review Vouchers and other creative tactics to ensure a market for these medicines may also persuade companies to develop drugs for long overlooked diseases such as malaria and tuberculosis. It's not yet clear whether these alternate funding schemes will prove attractive, but they may start making global health increasingly a part of business planning.
Advertisement

Related Content

Diagnostics For All Set To Take The Field For Clinical Trials
Global Health Funding Advocates Optimistic About Obama Administration
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA Priority Review Voucher Guidance Coming: Incentive Has Low Visibility
Summit Lends TB Program To Lilly Philanthropy
Novartis Coartem Malaria NDA May Be First For Priority Review Voucher
Treat and Trade: The New Priority Review Voucher Market
Best of the Blog: IN VIVO, June 2008
Venture Philanthropy: The New Venture Capital?
VaxInnate Inc.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel